Clinical Trials

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

Link :
Status : CLOSED
Population : Dedifferentiated liposarcoma
Description : I 907828 vs doxorubicin as first line therapy in DDLPS
PI : A. Razak, J. Noujaim, A. Smrke
Centers Opened : PMH, HMR, BCC
Phase : II/III
IIST/Pharma : Pharma